Research Progress of Pembrolizumab in the Treatment of Non-small Cell Lung Cancer

In recent years, Pembrolizumab, a programmed death-1(PD-1) inhibitor has shown considerable responses and good tolerance in the treatment of non-small cell lung cancer (NSCLC). In October 2015, Pebrolizumab was approved by FDA for the treatment of metastatic NSCLC with PD-L1 positive and disease progression after other treatments. With the development of clinical trials, the applications of Pembrolizumab in NSCLC treatment have gradually expanded. In this review, we summarized the current clinical status of Pembrolizumab in the treatment of NSCLC.